Ovid Therapeutics receives $53.9M from exercise of Series A warrants; issues 33.6M common shares

Ovid Therapeutics Inc.

Series A warrants from Oct 2025 private placement expired on April 17, 2026; 38,481,325 underlying shares.
Investors exercised 33,597,860 shares at $1.40 each and 4,883,464 pre-funded warrants at $1.399 each.
Gross proceeds of approximately $53.9 million to the company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.